Journal
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
Volume 14, Issue 4, Pages 277-282Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13506120701614032
Keywords
transthyretin; amyloidosis; liver transplantation; cardiomyopathy
Categories
Funding
- NCRR NIH HHS [RR-00750] Funding Source: Medline
- NIA NIH HHS [AG10133] Funding Source: Medline
- NIDDK NIH HHS [DK42111] Funding Source: Medline
Ask authors/readers for more resources
It has been hypothesized that transthyretin (TTR) amyloidosis may progress after orthotopic liver transplantation (OLT) as a result of continued amyloid fibril synthesis and deposition from normal TTR. To test this hypothesis amyloid fibrils were isolated from cardiac tissues of three patients who died 1 1/2 to 5 1/2 years after OLT: two with Val30Met and one with Thr60Ala TTR. The ratio of variant to normal TTR in each case was determined and compared with the ratio of variant to normal in cardiac tissues from seven patients who died with TTR amyloidosis but who had not had liver transplantation. Tissues from patients with TTR amyloidosis without OLT included three with Val30Met, two with Thr60Ala, one with Delta Val122, and one with Val122Ile. All tissues from patients without OLT had greater amounts of variant TTR than normal TTR except for the Val122Ile in which the ratio was 50:50. The overall median variant to normal ratio was 60:40 with a range of 50-70% variant. In contrast, the mean percentage of variant TTR in the three tissues from patients after OLT was 25% (range 20-35). These data are consistent with the continued deposition of normal TTR in cardiac tissue after liver transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available